Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.
Detailed safety analysis of CAR-T cell therapy in blood cancer patients gives doctors concrete benchmarks for managing side effects and improving patient outcomes.
This systematic review and meta-analysis consolidates safety data from CAR-T cell therapy clinical trials in relapsed/refractory multiple myeloma, pooling toxicity rates including CRS, ICANS, and cytopenias. The findings provide robust safety benchmarks for clinical practice and regulatory decision-making.
What the study was
- Study design
- Systematic review and meta-analysis of clinical trial safety data
- Population
- Adults with relapsed/refractory multiple myeloma treated with CAR-T cell therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- British Journal of Haematology
Why it surfaced
CAR-T safety meta-analysis in MM by established Athens group (Dimopoulos, Terpos). Published in BJH. Low novelty (safety profiles are being quantified incrementally), high clinical utility (safety data directly impacts treatment selection and consent), strong design (systematic review + meta-analysis). Score 7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.